COMPANY

Prolium Bioscience

HQ: New York, NY source · proliumbio.com ↗ · Mid-Atlantic

Keywords: immunology autoimmune diseases Systemic Sclerosis Systemic Scleroderma Scleroderma PRO-203

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Oct 27, 2025 Trial start 1: A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. source ↗

2027-01 (ESTIMATED) · 1 · A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. · NCT07641634

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07641634	A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.	1	Recruiting	Oct 27, 2025	2027-01 (estimated)